California Medi-Cal added Wegovy to its list for obesity in late 2024, and Indiana Medicaid expanded coverage in 2025
Glycaemic regulation models: In hyperglycaemic clamp models and oral glucose tolerance test paradigms in rodents, GLP-1R/GIPR co-activation with concurrent GCGR engagement did not produce the hyperglycaemic signal that might be predicted from glucagon receptor activation alone
Restraints High Cost and Potential Gastrointestinal Side Effects May Restrain Market Growth The relatively high cost of GLP-1 receptor agonists can be a significant restraint on market growth, particularly in regions with limited healthcare access or reimbursement
As reported, the Bacillota-to-Bacteroidota ratio was negatively correlated with the weight-gain effect
But constipation in certain instances, in rare instances, I mean, it can lead to obstruction and perforations
It represents an actual or potential health risk to athletes